Phase II trial reports leukemia remissions using engineered T cell therapy
1. 90% of relapsed B-cell acute lymphoblastic leukemia (ALL) patients achieved complete remission 1 month after an infusion of engineered T-cells.
2. All patients developed the cytokine-release syndrome requiring hospitalization.
Evidence Rating Level: 2 (Good)
Study Rundown: ALL is the most common form of childhood cancer. Up to a quarter of children with ALL will have recurrent or refractory disease. This phase II study looked at a new therapy involving engineered T-cells for relapsed B-cell ALL. The T-cells were engineered to target a protein found on the surface of B-cells called CD19. The hope was that these engineered T-cells would target and kill cancerous B-cells.
27 of 30 patients had complete remission 1 month after infusion of the T-cells. At six months of follow-up, there was a 67% event-free survival rate. The results compares favorably with existing treatments for relapsed ALL, which achieve rates of remission of less than 25% and lasting only 4 to 9 weeks. Adverse effects included the cytokine-release syndrome and B-cell aplasia. Excessive cytokine release as a result of massive T-cell activation leads to the cytokine-release syndrome, which can cause life-threatening complications. B-cell aplasia is an expected consequence of the treatment since the engineered T-cells do not discriminate between cancerous and healthy B-cells. In fact, B-cell aplasia may be a useful marker of continued efficacy of the CTL019 T-cells.
Click to read the study, published today in NEJM
Relevant Reading: Chimeric Antigen Receptor- Modified T Cells for Acute Lymphoid Leukemia
In-Depth: This phase II clinical trial treated 30 patients with CTL019 T-cell therapy to evaluate the safety and feasibility of this therapy. There was a higher proportion of CTL019 T-cells in the 27 patients who achieved remission at 1 month versus the 3 who did not. Three patients who initially achieved remission had relapses after losing the CTL019 T-cells. Notably, another three patients had relapses after their leukemia cells stopped expressing CD19.The study achieved an overall survival of 78% (95% CI, 65 to 95). All patients experienced the cytokine-release syndrome, and 27% developed a severe reaction.
More from this author: Early risk factor for progression of cystic fibrosis identified, Gut microbes implicated in stroke and heart attacks: new dietary link, New leukemia mutation offers therapeutic targets, Childhood ADHD associated with increased risk of suicide, A marker of aggressive liver cancer and potential therapeutic target identified
Image: PD
©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.
